PUMA BIOTECHNOLOGY, INC. - Common Stock, par value $0.0001 per share (PBYI)

CUSIP: 74587V107

Q2 2022 13F Holders as of 30 Jun 2022

Holder snapshot 7 signals
Share change
-1,460,025
Put/Call ratio
118%
SEC-reported price per share
$2.85
Number of holders
77
Value change
-$4,139,901
Number of buys
33
Open additional details 1 more signal available
Number of sells
60
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
54,055,988

Security key

74587V107

Report period

Q2 2022

Institutions

77

Top holders

10

Ownership snapshot

Top reported holders of PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Camber Capital Management LP
Disclosed value leader
Camber Capital Management LP
Comparable rows
0/15
Latest evidence
31 Mar 2022
13F Highest disclosed value: $11,520,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Camber Capital Management LP has the largest disclosed position value at $11.52M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Camber Capital Management LP's linked filing trail.
Disclosed position value Top 5
Camber Capital Management LP $11.52M
VANGUARD GROUP INC $9.98M
BlackRock Finance, Inc. $9.73M
MILLENNIUM MANAGEMENT LLC $5.51M
Athyrium Capital Management, LP $5.16M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Camber Capital Management LP
13F
Company
13F
—
denominator unverified
$11,520,000
4,000,000 shares
— 31 Mar 2022
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$9,985,000
3,466,840 shares
— 31 Mar 2022
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$9,733,000
3,379,684 shares
— 31 Mar 2022
MILLENNIUM MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$5,506,000
1,911,675 shares
— 31 Mar 2022
Athyrium Capital Management, LP
13F
Company
13F
—
denominator unverified
$5,161,000
1,792,114 shares
— 31 Mar 2022
RENAISSANCE TECHNOLOGIES LLC
13F
Company
13F
—
denominator unverified
$5,101,000
1,771,235 shares
— 31 Mar 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
77
Shares
27,896,143
Rows available
77
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2022 vs Q1 2022 Across Filers

Q1 2022 holders
95
Q2 2022 holders
77
Holder diff
-18
Investor Q1 2022 Shares Q2 2022 Shares Share Diff Share Chg % Q1 2022 value Q2 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .